Research Funding Opportunity to Assess the Impact of Extended-Infusion of Beta-lactam Antibacterial Drugs on Development of Beta-lactam Resistance and Patient Outcomes

If your email program has trouble displaying this email, view as a webpage. Research Funding Opportunity to Assess the Impact of Extended-Infusion of Beta-lactam Antibacterial Drugs on Development of Beta-lactam Resistance and Patient Outcomes   Dear Colleagues, I would like to inform you that the FDA is accepting proposals focused on research assessing the impact of extended-infusion of beta-lactam antibacterial drugs on development of beta-lactam resistance and patient outcomes. Specifically, research proposals focused on evaluating the impact of dosing strategies for beta-lactam antibacterial drugs for serious infections caused by gram-negative pathogens on development of beta-lactam resistance and patient outcomes will be prioritized. Proposals should be submitted to the Broad Agency Announcement (proposal preparation and submission can be found on page 35): FDABAA-21-00123 Additional information to apply to this open announcement is attached here (PDF). Please note that the Quad Chart and White Paper are due by January 28, 2021. Please feel free to share this information with others who may be interested in applying. Thank you.

Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA